




FIG. 1A

FIG. 1B

FIG. 1C




FIG. 2




FIG. 3




FIG. 4

	PH1 Young Adult Subjects (ages 18-35) n=30		PH1b Older Adult Subjects (ages 50-75) n=130	
	IVX-121 n (%)	Placebo n (%)	IVX-121 n (%)	Placebo n (%)
Any serious adverse event (AE)	0	0	0	0
Any AE of special interest	0	0	0	0
Any AE leading to death or study discontinuation	0	0	0	0
Any grade 4 (life-threatening) AE	0	0	0	0
Any related Medically-Attended AE	0	0	2 (1.8)	0
Any unsolicited adverse event (through day 28)				
Mild	25 (29.8)	2 (33.3)	27 (24.3)	7 (36.8)
Moderate	33 (39.3)	1 (16.7)	21 (18.9)	2 (10.5)
Severe	1* (1.2)	0	3* (2.7)	0

FIG. 5




FIG. 6




FIG. 7




FIG. 8

28 days post administration	Younger Adults - RSV/A					Younger Adults RSV/B		Older Adults - RSV/A					Older Adults RSV/B	
	Younger Adults - RSV/A			Younger Adults RSV/B		Older Adults - RSV/A			Older Adults RSV/B					
	GMT (IU/ml)	95% CI	Seroreponse 4 fold rise	GMT (IU/ml)	95% CI	GMT (IU/ml)	95% CI	Seroreponse 4 fold rise	GMT (IU/ml)	95% CI	Seroreponse 4 fold rise	GMT (IU/ml)	95% CI	
25 mg (no alum)	6451	3667-10482				1542-5971	5403	3282-8893						
75 mg (no alum)	7657	4507-13111				2597-8207	6362	3178-12733						
250 mg (no alum)	5861	3531-9592				2821-8209	7561	4244-13471						
25 mg (+ alum)	2623	1619-3764	3.6	not reported	1059-3666	2652	1619-4314	1.8	not reported	1402-5250				
75 mg (+ alum)	3032	1906-4824	3.0	not reported	1862-3136	5733	3355-9799	3.6	not reported	1340-3794				
250 mg (+ alum)	7665	4115-14278	3.9	not reported	2966-7194	5886	3157-10962	3.9	not reported	2127-5898				
Placebo	1100	744-1525	1.0	0	434-958	1692	972-2944	1.4	10-50%	1274-2560				

FIG. 9